Navigating Regulatory Hurdles: How FDA and EMA Approvals Shape the Doxorubicin Market Evolution
Regulatory compliance is a make-or-break factor for pharmaceutical markets, and the doxorubicin sector is no exception. As a drug with well-documented benefits but also risks—including cardiotoxicity and secondary malignancies—doxorubicin’s development, labeling, and distribution are tightly governed by agencies like the FDA and EMA. These regulations directly impact market...
0 Yorumlar 0 hisse senetleri 21 Views 0 önizleme